Insider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $23,126.46 in Stock

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 3,318 shares of the stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $6.97, for a total value of $23,126.46. Following the transaction, the insider now directly owns 5,550,771 shares in the company, valued at approximately $38,688,873.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The shares were sold at an average price of $6.57, for a total value of $45,333.00.
• On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The stock was sold at an average price of $6.54, for a total value of $26,362.74.
• On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The shares were sold at an average price of $6.35, for a total value of $16,332.20.
• On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The stock was sold at an average price of $6.10, for a total transaction of $19,050.30.
• On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The stock was sold at an average price of $6.66, for a total transaction of $32,700.60.

NeuroPace Price Performance

NeuroPace stock opened at $6.47 on Monday. The firm has a fifty day moving average of $7.05 and a 200-day moving average of $8.35. NeuroPace, Inc. has a 52-week low of $5.73 and a 52-week high of $18.15. The company has a quick ratio of 5.47, a current ratio of 6.37 and a debt-to-equity ratio of 5.97. The firm has a market capitalization of $186.13 million, a P/E ratio of -5.44 and a beta of 1.78.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.03. The firm had revenue of $19.26 million during the quarter, compared to the consensus estimate of $18.30 million. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The firm’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.36) EPS. As a group, analysts predict that NeuroPace, Inc. will post -1.08 EPS for the current year.

Analyst Ratings Changes

NPCE has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $18.00 price target on shares of NeuroPace in a research note on Wednesday, August 14th. Morgan Stanley dropped their price objective on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. Finally, Wells Fargo & Company reduced their target price on NeuroPace from $20.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Institutional Investors Weigh In On NeuroPace

Several hedge funds have recently modified their holdings of the stock. Rhumbline Advisers acquired a new stake in NeuroPace in the second quarter valued at approximately $111,000. Financial Advocates Investment Management lifted its position in shares of NeuroPace by 50.0% during the second quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock worth $113,000 after purchasing an additional 5,000 shares in the last quarter. Hillsdale Investment Management Inc. acquired a new position in shares of NeuroPace during the first quarter worth $155,000. XTX Topco Ltd increased its stake in NeuroPace by 56.1% during the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after buying an additional 8,643 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in NeuroPace in the 2nd quarter worth $257,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.